Dietary Supplements for the Treatment of Angelman Syndrome

NCT00348933 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 90

Last updated 2012-09-24

Study results available
· View outcomes & findings →

Summary

Angelman syndrome (AS) is a complex genetic disorder that affects the nervous system. The purpose of this study is to determine the effectiveness of certain dietary supplements in treating the symptoms of AS.

Conditions

Interventions

DRUG

Betaine

100-200 mg per kg per day by mouth with a maximum of 6 grams divided in two daily doses

DRUG

Creatine

200 mg per kg per day with a daily maximum of 5 grams divided in two daily doses

DRUG

Metafolin

0.5 mg per kg per day by mouth with a maximum of 8 milligrams divided in two daily doses

DRUG

Vitamin B12

1 mg by mouth per day for all weights and ages

Sponsors & Collaborators

Principal Investigators

  • Arthur L. Beaudet, MD · Department of Molecular and Human Genetics, Baylor College of Medicine

  • Carlos A. Bacino, MD · Department of Molecular and Human Genetics, Baylor College of Medicine

  • Wen-Hann Tan, BMBS · Harvard Medical School, Children's Hospital Boston

  • Lynne M. Bird, MD · Division of Dysmorphology/Genetics, Children's Hospital San Diego, Department of Pediatrics, University of California, San Diego

  • Steven A. Skinner, MD · Greenwood Genetic Center

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
1 Day
Max Age
5 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2006-07-31
Primary Completion
2010-02-28
Completion
2010-02-28

Countries

  • United States

Study Locations

More Related Trials

Entities

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00348933 on ClinicalTrials.gov